Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Poolbeg Pharma #POLB is revolutionising the biopharma landscape! Leveraging #AI, they're accelerating drug discovery and setting new standards in infectious disease treatment. Game-changer!
tinyurl.com/3vem9b9c
https://x.com/lemminginvestor/status/1709293600456974776?s=46
I had an hour with SOH yesterday. Much was discussed, and some important historical context related to the accounts, bad debt provision, SweetBiotix in particular.
I did record the conversation with SOH's approval. However, the conversation was never intended to be in a podcast format; therefore not the right quality. I have handed the audio file to my son, Alex, to do as he pleases. I do not expect to be sitting on it because I feel some encouraging content needs to be shared. I am hopeful Alex can produce something for the weekend. He's too big for me to bully, so bear with me.
Yes indeed. PBX move to a more liquid market is critical, as I have often argued, and so has Alex recently. I have asked about this before. If I understand or recall the previous discussion I had with SOH, he will not be able to provide specifics because it affects funds and has tax status implications. It won't do any harm to propose a more rapid switch or dual listing.
I'll be taking a call from SOH this afternoon. If anyone has a query, etc., let me know here or contact me your usual way.
SOH note on the bad debt provision should provide assurance for those concerned. Update to 30 September editorial. Open source. https://lemminginvestor.substack.com/p/optibiotix-health-plc-648
Trigger warning folks :)
Back in July, I eyed OptiBiotix at 20.8p/share. Despite critiques of their communication, I saw a shift & added them to my watchlist. But why did the 19th July RCS boost shares by 150% when its info was missing in the 29th August RNS? 🤔 Now, there's talk of a Boots agreement.
https://twitter.com/LEMMINGINVESTOR/status/1708873927215239406
Mike's likely enjoying orange tangos on a Jamaican beach after a 130% gain; I can't help but spotlight ME International. Mike was spot-on about the rise of instant-service vending. #MEGP Japan acquisition from FUJIFILM isn't just a buy—it's a masterstroke, placing ME Group Japan K.K. as a market leader.
tinyurl.com/ytx9s3a7
https://x.com/lemminginvestor/status/1708828402503860690?s=46
While I'm at it... https://lemminginvestor.substack.com/p/probiotix-health-plc-a59
Big pharma needs more souls like you, lord. Sell misery and boost their coffers.
Btw, I respectfully suggest you own whatever mistakes YOU have made rather than seek to blame others; it's the mature attitude that wins in the end. I/we provide research and commentary, not share tips. If your timing has impacted your success, I am sorry - but own it.
I also suggest you filter my account.
I think my son is senile because he seems to forget just how long I was patient.
By Alex Langton | 30 September 2023
I have an investment in OptiBiotix Health.
OptiBiotix Health is a company that aims to be a prominent player in the life sciences industry by developing innovative solutions for obesity, cardiovascular disease, diabetes, and skincare. The company has released its unaudited financial results for the first half of 2023. The report shows that the company is experiencing robust growth but is also facing operational losses. This presents a multifaceted narrative for investors, who should consider the impact of the pandemic on the company’s prior periods and how it has affected bad debt. However, the company is confident that the debt will be paid in due course.
https://lemminginvestor.substack.com/p/optibiotix-health-plc-648
Securing intellectual property rights is paramount in a world where medical innovation is the linchpin of progress. Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company at the forefront of addressing diseases with a high unmet medical need, has emerged victorious in a pivotal patent dispute. The conclusion of this matter is not just a win for Poolbeg.
https://lemminginvestor.substack.com/p/poolbeg-pharma-plc-f4a
Https://lemminginvestor.substack.com/p/poolbeg-pharma-plc-d92
Woof,
I understand the rationale behind raising £1m or even £2m ahead of potentially more difficult periods. The later a company waits to raise funds, the larger the discount and usually the lower the amount that can be raised. However, I asked a question and it seems that although SA repeated the same warning he had used with me, he was dismissive of my concerns. Nonetheless, I appreciate where you and TW are coming from, and it does make sense to raise funds in advance. Perhaps earlier than planned clinical study paid for by Croda has offered SA more reassurance on the timing of revenues from the product launches. This is a wild guess, of course.
Ray,
Now you have the opportunity to listen to the interview, perhaps you can be good enough to appraise it and actually contribute to the discussions rather than constantly complain about £35 across the forums. :)
That is an excellent point, Clio. Moreover, IMHO, the MN has a member of its scientific team in both camps simultaneously. Out of respect for Stuart, I could not just throw the MN name on his lap and expect him to say, well done, you nailed. The NOMAD would have had kittens. However, without names, I did propose my hypothesis. I stand by my hypothesis on the identity of the MN seeking to take control of the AxisBiotix pillar.
Woof,
A well-considered post. I hope that does not come across as patronising.
Indeed, an MN deal involving an upfront payment worth c£3m would ease concerns from people like yourself who have pulled up a seat to sit on the sidelines with a watching brief. It is all about one's comfort with the level of risk, and SBTX carries risks you rightly highlight, as have I.
Stuart recently stated we would never rule out a fundraiser. However, like you, I do not see an MN deal being signed off with a wad of cash before the study results. This leaves AxisBiotix -Ps sales building steadily with a c80% retentions and Croda revenues, which I believe will be as early as the end of Q1 but likely to be H2. If this is the case, SBTX should not be required to come back to the market to raise more funds. You said it yourself: the market controls the cash, and SBTX had no problems raising the money when there was plenty of evidence other Companies, including OPTI, could not raise what they wanted, and if they did, it was typically at a significant discount. Croda is a very useful indemnity if you need to raise cash. It's likely to be less than the prior £3.5 gross, and a door could open for SBTX to request an advance from Croda sales. I must be clear: Stuart never floated this idea in our conversations.
The fact that SBTX raised what it wanted at a minimal discount is quite telling, be it from someone who may be wearing rose-tinted glasses. Stuart and Manprit will have been in detailed discussions with Croda before crunching the numbers.
No mergers or acquisitions appear to be completed before the Croda launch. The small team led by Stuart is working tirelessly, and it is more of a matter of time constraints than anything else. The primary focus seems to be on the study, oral care, and Croda. During the interview, it became evident that mergers or acquisitions are unlikely to involve cash or shares but could potentially include a mixture of CLNs, asset debt, and shares. Additionally, the deal must benefit the business overall and be accretive.
The territory expansion of AxisBiotix-Ps also helps the MN deal, as a regulatory pathway has been established in a post-Brexit world where we are led to believe Brexit Britain is doomed.
Based on my understanding, SBTX had £1.2 million before raising £3.5 million gross. The company's cash burn is decreasing and is expected to be below the c£200k monthly. In my opinion, I don't think the company will need to raise any more funds to continue its existing business strategy. The launch of Croda has significantly changed the risk landscape, and I believe it will bring high volumes from a range of high-profile household names rather than just the soft launch we saw with AxisBiotix-Ps.
Spuddy,
Trolls like Moninan fail to understand that companies such as POLB are disruptive fledglings with no notable revenues at such an early stage. Moreover, they fail to comprehend the business model, which makes them blind to the opportunities that others see and have the patience and conviction to maintain their investment. Although it is fine to have a contrarian point of view, constantly harassing and avoiding answering difficult questions - such as the ones I have asked - is a waste of time. Moninan often shares misinformation about my opinions, which are frequently unrelated to the company. As a result, I have decided to filter his comments, as he ignores them and only engages in badger-baiting. It is worth noting that volatility in the SP is to be expected given the nature of fledgling companies, and it will not be smooth sailing for companies such as POLB because retail PIs are a thirsty lot when it comes to news.